Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
27 934 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX XXXXXX X XXXXXXXXX XXXXXXXXX (XX) 2020/1182

xx dne 19. xxxxxx 2020,

kterým se xxx xxxxx přizpůsobení xxxxxxxxxxx a xxxxxxxxx xxxxxxx xxxx xxxx 3 xxxxxxx VI xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (ES) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx a xxxxxx látek a xxxxx

(Xxxx s xxxxxxxx xxx XXX)

XXXXXXXX XXXXXX,

x xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x ohledem xx xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1272/2008 ze xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxx x směsí, x xxxxx a xxxxxxx xxxxxxx 67/548/XXX x 1999/45/ES x x změně xxxxxxxx (XX) č. 1907/2006 (1), x zejména xx xx. 37 odst. 5 uvedeného xxxxxxxx,

xxxxxxxx x těmto důvodům:

(1)

Tabulka 3 x části 3 xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 obsahuje seznam xxxxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxxxxx xxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx („xxxxxxxx“) xxxx x souladu x xxxxxxx 37 xxxxxxxx (ES) x. 1272/2008 předloženy xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x označení xxxxxxxxx xxxxx x xxxxxxxxxxx xxxx xxxxxxx xxxxxxxxxxxxxxx klasifikací a xxxxxxxx xxxxxxxxx xxxxxx xxxxx. Na xxxxxxx xxxxxxxxxx&xxxx;(2) x xxxxx xxxxxxx, xxxxx xxxxx Xxxxx pro posuzování xxxxx („XXX“) xxxxxxxx, xxxxx i připomínek xxxxxxxxxxxx xxxxx, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx xxxxxx harmonizované xxxxxxxxxxx a xxxxxxxx xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx výboru XXX xxxx:

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxxxxxx xxxxxxx... %[X ≤ 70 %],

—

xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx xxxxxx z xxxxxxx xxxxxxx (x xxxxxxx &xx; 3 μx,xxxxx > 5 μx a xxxxxx xxxxx ≥ 3:1),

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, trimethoxy(vinyl)silanu,

—

stanovisko ze xxx 8. června 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx dimethyl-disulfidu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxx xxxx,

—

xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Cu-HDO],

—

stanovisko xx xxx 14. září 2018 xxxxxxx dioktyltin-dilaurátu, [1] xxxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2],

—

xxxxxxxxxx xx dne 30. listopadu 2018 xxxxxxx dibenzo[def,p]chrysenu, dibenzo[a,l]pyrenu,

—

stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (XXX), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, tetraglymu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxx (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx 2,2-bis(brommethyl)propan-1,3-diolu,

—

stanovisko xx dne 14. xxxx 2018 ohledně xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. xxxxx 2019 xxxxxxx 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (ISO), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-onu, xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx ze xxx 8. června 2018 xxxxxxx xxxxxxxxxx xxxxxxxx …%,

—

xxxxxxxxxx xx dne 14. září 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [xxxxxxxxxxx xxxxxxxx x xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně (xxxxx-XXX-xxxxx)xxxxxxxxxxx draselného, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [X-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, mecetronium-ethyl-sulfátu [XXX],

—

xxxxxxxxxx ze dne 9. xxxxxx 2018 xxxxxxx (2RS)-2-[4-(4-chlorfenoxy)-2(trifluoromethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-olu, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (T-4)-bis[1-(hydroxy-kappa-O)pyridin-2(1H)-thionát-kappa-S]zinku,

—

stanovisko ze xxx 30. listopadu 2018 ohledně 3-chlor-4-(chlormethyl)-1-[3-trifluormethyl)fenyl]pyrrolidin-2-onu, xxxxxxxxxxxxxxx (ISO),

—

stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx 2-methyl-1,2-benzothiazol-3(2H)-onu, [XXXX],

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx xx xxx 15. xxxxx 2018 xxxxxxx 5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamidu, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, penflufenu,

—

stanovisko xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxxxxxx (XXX), xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxx (ISO), N-allyl-4,5-dimethyl-2(trimethylsilyl)thiofen-3-karboxamidu,

—

stanovisko xx xxx 9. xxxxxx 2018 ohledně xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx bez xxxxxxxx, extrahovaný superkritickým xxxxxx uhličitým],

—

stanovisko ze xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx xxxxxxx …%[X&xx; 70 %],

—

xxxxxxxxxx z 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [D4],

—

stanovisko xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxx-xxxxxxx (XXX), X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [DOTE],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx olova,

—

stanovisko xx dne 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx m-bis(2,3-epoxypropoxy)benzenu, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx tribenuron-methylu (XXX), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxx (XXX), xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx mesotrionu (XXX), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (ISO), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [OIT],

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (XXX), 3-hydroxy-5-methylisoxazolu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), trans-5-(4-chlorfenyl)-N-cyklohexyl-4-methyl-2-oxo-3-thiazolidin-karboxamidu,

—

stanovisko ze xxx 9. xxxxxx 2018 ohledně pymetrozinu (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), xxxxxxx xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthematu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx-xxxxx, ethylmethylketoximu, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxx 2-(1-(diethylaminohydroxyfenyl) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx x xxxxx xxxxx (číslo XXX 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (olovo x xxxxxx; [průměr xxxxxx &xx; 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [xxxxxx xxxxxx ≥ 1 xx];)), RAC ve xxxx xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxx použít xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxxx i xxxxxxxxx formu. Xxxxx xxxxxxxx x xxxxx xxxxxxxxx xxxxxxxxxxx celistvé xxxxx, xxxxxx xxxxxxxxx xxxxx, xx xxxxxxxxxx xxxxxxx výrobě xxxxxx x xxxxxxxx k xxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x celistvých x xxxxxxxxxx xxxxx xxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx x xxxxxxx XX xxxx RAC xxxxxxx xxxxx xxxxxxxxx xxxx, xxx xx xxx xx xxxxxxxxx x xxxxxxxxx formu xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx klasifikace. Xxxxx xxxx byly xxxxxxxxxx xxxx vědecké xxxxxxxx, x nichž vyplývá, xx xxxxxxxxxxxxxxx xxxxxxxxxxx xxx xxxxxxxxx formu, xxx ji doporučilo xxxxxxxxxx xxxxxx XXX, xxxxxx být xxxxxx. Xxxxxxxxxxxxxxx klasifikace pro xxxxxxxxx formu proto xxxxxx zařazena do xxxxxxx VI xxxxxxxx (XX) č. 1272/2008, xxxxx XXX xxxxxx xxx xxxxxxx předložit xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx jde x xxxxx 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), xxx xxxxx xxxxxxxxxxxxx „xxxxxx xxxxxxxx (xxxxxxxxx)“ xxxx předloženy xxxx xxxxxxx poznatky, xx xxxxxxx xxxxxxx, xx xxxxxxxxxxx xxx xxxx xxxxx nebezpečnosti xxxxxxxxxxxx xx xxxxxxxxxx xxxxxx XXX, jež xx xxxxxxx xx xxxxxxxx xxxxxxx, xxxxxx xxx xxxxxx. Xxxx xxxxx nebezpečnosti by xxxxx neměla být x xxxxxxx XX xxxxxxxx (ES) x. 1272/2008 xxxxxxx, dokud XXX xxxxxx xxx xxxxxxx xxxxxxxxx k xxxxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; xxxxxxx xxxxxxx xxxxx xxxxxxxxxxxxx, x xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxx RAC, xx zařazeny xxx xxxx.

(5)

Xxxxxxxx (ES) x. 1272/2008 by proto xxxx xxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx harmonizovaných xxxxxxxxxxx by xxxxxx xxx, x xxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx potřebují xxxxxxx xxxx xx xx, xxx přizpůsobili xxxxxxxxxx x balení xxxxx x xxxxx novým xxxx xxxxxxxxxxx xxxxxxxxxxxx x xxxxxxx xxxxxxxxx xxxxxx. Tato xxxx xx xxxxxx xxxxxxxx x tomu, aby xxxxxxxxxx xxxx xxxxxxxx xxxx přijmout xxxxxxxx xxxxx x zajištění xxxxxxxx dodržování xxxxxxx xxxxxxxx xxxxxxxxx, které xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx podle xxxxxx nařízení. Xxxx xxxxxxxxx xxxxx zahrnovat xxxxxxxxx xxxxxxxxx v xx. 22 xxxx. 1 písm. x) xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 1907/2006 (3) nebo xxxxxxxxx xxxxxxxxx x xxxxxx 50 nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) x. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx by xxxx xxxx být xxxxxxxx, xxx xxxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, označování x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx xxxx použitelnosti xxxxxx nařízení. Xx xx x xxxxxxx x přístupem xxxxx xx. 61 xxxx. 2 nařízení (XX) x. 1272/2008,

PŘIJALA XXXX XXXXXXXX:

Xxxxxx 1

Xxxxx nařízení (XX) x. 1272/2008

Tabulka 3 x xxxxx 3 přílohy VI xxxxxxxx (XX) x. 1272/2008 xx xxxx x xxxxxxx x xxxxxxxx xxxxxx xxxxxxxx.

Xxxxxx 2

Xxxxx x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx x xxxxxxxx dvacátým dnem xx vyhlášení x Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.

Xxxxxxx xx xxx xxx 1. xxxxxx 2022.

Xxxxxxxx xx druhého xxxxxxxxxxx tohoto xxxxxx xxxxx xxx xxxxx x xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x baleny x xxxxxxx s xxxxxxxxx (ES) x. 1272/2008 ve xxxxx xxxxxx nařízení xxxxx xxxxx xxxx 1. xxxxxx 2022.

Xxxx nařízení xx xxxxxxx v xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx xxxxxxx.

X Xxxxxxx xxx 19. května 2020.

Xx Xxxxxx

Xxxxxx XXX XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx této xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) č. 1907/2006 xx xxx 18. xxxxxxxx 2006

x xxxxxxxxxx, hodnocení, povolování x xxxxxxxxx xxxxxxxxxx xxxxx, o zřízení Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, o xxxxx směrnice 1999/45/XX x x xxxxxxx xxxxxxxx Xxxx (XXX) x. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, směrnice Xxxx 76/769/XXX x směrnic Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX x 2000/21/XX (Xx. xxxx. L 396, 30.12.2006, x. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx parlamentu x Rady (EU) x. 528/2012 xx xxx 22. května 2012

x xxxxxxxx xxxxxxxxxx xxxxxxxxx xx xxx x xxxxxx xxxxxxxxx

(Xx. xxxx. L 167, 27.6.2012, x. 1).

XXXXXXX

X xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 se xxxxxxx 3 x části 3 xxxx xxxxx:

1)

Xxxxxxxx xx xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx ES

Číslo XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx koncent. xxxxxx, xxxxxxxxxxxxx faktory x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx nebezpečnosti

Kódy standardních xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx symbolů a xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx x nebezpečnosti

„007-030-00-3

kyselina dusičná …% [C ≤ 70 %]

231-714-2

7697-37-2.

Xx. Xxx. 3

Xxxxx Xxx. 3

Skin Xxxx. 1 A

H272

H331

H314

GHS03

GHS06

GHS05

Dgr

H272

H331

H314

EUH071

Ox. Xxx. 3; X272: X ≥ 65 %

xxxxxxxxx: XXX = 2,65 xx/x (xxxx)

Xxxx Xxxx. 1 A; X314: X ≥ 20 %

Xxxx Xxxx. 1X; H314: 5 % ≤ X &xx; 20 %

X“

„014-048-00-5

xxxxxx x xxxxxxx xxxxxxx (x xxxxxxx < 3 μx, délce &xx; 5 μx x s xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 3

XXXX XX 3

XXXX XX 1

Eye Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X225

X331

X301

X336

X370 (xxxxx xxxxxxx cesty, vdechnutí)

H319

H317

H400

H410

GHS02

GHS06

GHS08

GHS09

Dgr

H225

H331

H301

H336

H370 (xxxxx dýchací xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: ATE = 5 mg/l (xxxx)

xxxxxx: XXX = 190 xx/xx TH

M = 1

X = 10“

„029-024-00-X

xxxxxxxxxxx xxx;

[xxxxx částic: xx 0,9 mm x xx 6,0 xx; xxxxx xxxxxx: xx 0,494 xx 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Xxxxxxx 2

H411

GHS09

H411“

„029-025-00-5

bis(N-hydroxy-N-nitrosocyklohexylaminato-O,O’)měď;

bis(N-cyklohexyl-diazenium-dioxy)-měď;

[Cu-HDO]

239-703-4

312600-89-8

15627-09-5

Flam. Xxx. 1

Xxxxx Xxx. 4

XXXX XX 2

Eye Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (játra)

H318

H410

orální: XXX = 360 xx/xx XX

X = 1

X = 1“

„050-031-00-9

dioktylcín-dilaurát; [1]

xxxxxxx, xxxxxxx-, bis(koko xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1X

XXXX XX 1

H360D

H372 (imunitní xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Xxx. 4

XXXX XX 2

Aquatic Chronic 1

X360X

X302

X373 (oči, kůže, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: ATE = 500 xx/xx TH

M = 100“

„603-238-00-9

bis(2-(2-methoxyethoxy)ethyl)-ether; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (XXX);

(2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx

–

76738-62-0

Xxxx. 2

Xxxxx Xxx. 4

Acute Tox. 4

Xxx Xxxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: XXX = 3,13 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 490 xx/xx XX

X = 10

M = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1B

Muta. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Sens. 1

H317

GHS07

Wng

H317“

„605-041-00-3

2-(4-terc-butylbenzyl)propanal

201-289-8

80-54-6

Repr. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-chlor-2-methylfenoxy)ethanethioát; X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxx

246-831-4

25319-90-8

Xxxxx Xxx. 4

XXXX XX. 2

Aquatic Xxxxx 1 Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 xx/xx TH

M = 10

M = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X302

X373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: ATE = 500 xx/xx XX

X = 10

X = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Acute 1

Xxxxxxx Chronic 1

X400

X410

XXX09

Xxx

X410

X = 1000

X = 1000“

„607-743-00-5

X-(+)-xxxxxx xxxxxxxx;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1C

Eye Xxx. 1

H314

H318

GHS05

Dgr

H314

EUH071“

„607-744-00-0

2-methoxyethylakrylát

221-499-3

3121-61-7

Flam. Liq. 3

Xxxx. 2

Xxxx. 1X

Xxxxx Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 xx/x (xxxx)

xxxxxx: XXX = 404 xx/xx TH“

„607-745-00-6

glyoxylová kyselina …%

206-058-5

298-12-4

Xxx Dam. 1

Xxxx Xxxx. 1B

H318

H317

GHS05

GHS07

Dgr

H318

H317

B“

„607-746-00-1

natrium-N-(hydroxymethyl)glycinát;

[formaldehyd xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

XXXX XX 3

Xxxx Xxxxx. 2

Eye Xxxxx. 2

Xxxx Sens. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: ATE = 3 xx/x (xxxxx xxxx mlha)

orální: XXX = 1&xxxx;100 mg/kg XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, draselná xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Xxxxx Xxx. 3

XXXX XX 2

Xxxx Xxxxx. 2

Eye Xxx. 1

Xxxxxxx Xxxxxxx 2

X228

X301

X373 (játra)

H315

H318

H411

GHS02

GHS06

GHS08

GHS05

GHS09

Dgr

H228

H301

H373 (xxxxx)

X315

X318

X411

xxxxxx: XXX = 136 xx/xx TH“

„612-294-00-3

mecetroniumetilsulfát;

N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfát;

mecetronium-ethyl-sulfát;

[MES]

221-106-5

3006-10-8

Skin Xxxx. 1

Xxx Dam. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

M = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

M = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Chronic 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Xxx. 2

Xxxxx Tox. 3

XXXX XX 1

Xxx Dam. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H360D

H330

H301

H372

H318

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H360D

H330

H301

H372

H318

H410

inhalační: ATE = 0,14 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 221 xx/xx TH

M = 1&xxxx;000

X = 10“

„613-334-00-2

xxxxxxxxxxxxxx (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Tox. 4

Xxxx Sens. 1

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 mg/kg TH

M = 100

X = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXXXX]

264-843-8

64359-81-5

Xxxxx Xxx. 2

Xxxxx Xxx. 4

Skin Xxxx. 1

Eye Xxx. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H330

H302

H314

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H314

H317

H410

EUH071

inhalační: XXX = 0,16 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Xxxxx. 2; X315: 0,025 % ≤ X &xx; 5 %

Xxx Xxxxx. 2; H319: 0,025 % ≤ X &xx; 3 %

Xxxx Sens. 1 X; X317: X ≥ 0,0015 %

X = 100

M = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Xxx. 4

Acute Xxx. 3

Xxxx Corr. 1X

Xxx Xxx. 1

Skin Xxxx. 1 A

Aquatic Xxxxx 1

Xxxxxxx Chronic 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX

xxxxxx: XXX = 175 xx/xx TH

Skin Sens. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(difluormethyl)-1-methyl-N-(3‘,4’,5’-trifluorbifenyl-2-yl)pyrazol-4-karboxamid;

fluxapyroxad

–

907204-31-3

Lact.

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

M = 1“

„616-230-00-5

N-(hydroxymethyl)akrylamid; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1X

XXXX XX 1

H350

H340

H372 (xxxxxxxxx xxxxxxx systém)

GHS08

Dgr

H350

H340

H372 (xxxxxxxxx xxxxxxx systém)“

„616-231-00-0

5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamid; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 1

X = 1“

„616-232-00-6

iprovalikarb (XXX);

xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx

–

140923-17-7

Xxxx. 2

X351

XXX08

Xxx

X351“

„616-233-00-1

xxxxxxxxxx (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

H373

H411

GHS08

GHS09

Wng

H373

H411“

„650-057-00-6

Margosa, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx semen xxxxxxxx Azadirachta xxxxxx xxx skořápek, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx uhličitým]

283-644-7

84696-25-3

Aquatic Xxxxxxx 3

H412

H412“

2)

položky xxxxxxxxxxxx xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 x 617–006–00-X xx nahrazují xxxxxx xxxxxxxxx:

Xxxxxxxx číslo

Chemický xxxxx

Xxxxx XX

Xxxxx CAS

Klasifikace

Označení

Specifické xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx výstražných xxxxxxx x xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx doplň. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Xxx. 2

Xxxxx Xxx. 1

Skin Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Xxx. 2; X272: C ≥ 99 %

Ox. Xxx. 3; X272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Aquatic Xxxxxxx 1

X361x ***

H410

GHS08

GHS09

Wng

H361f ***

X410

X = 10“

„015-134-00-5

pirimifos-methyl (ISO);

O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforothioát

249-528-5

29232-93-7

Acute Xxx. 4

STOT RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X302

X372 (xxxxxxx xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1&xxxx;000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Xxx 1

Xxxxx. Xxx

Xxxxx Xxx. 1

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1B

Acute Xxx. 2

STOT XX 1

Xxxxxxx Xxxxxxx 3

X360X

X330

X372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

H412

Repr. 1X; X360 X: X ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (xxxxx xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [DOTE]

239-622-4

15571-58-1

Repr. 1X

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (imunitní systém)

H400

H410

GHS08

GHS09

Dgr

H360D

H372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx xxxxxx; [xxxxxx xxxxxx < 1 mm]

231-100-4

7439-92-1

Repr. 1 X

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H360FD

H362

H400

H410

GHS08

GHS09

Dgr

H360FD X362

X410

Xxxx. 1 X; X360X: X ≥ 0,03 %

X = 1

M = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Xxx. 4

Skin Xxxxx. 2

Xxx Irrit. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 4

Skin Xxxxx. 2

Eye Xxxxx. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 xx/xx XX orální: XXX = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX RE 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Xxx. 3

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (prach nebo xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Acute Xxx. 3

Xxxxx Tox. 2

XXXX XX 1

Xxxxxxx Xxxxx 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermální: XXX = 300 xx/xx XX xxxxxx: XXX = 30 xx/xx XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X361x

X373 (xxx, xxxxxxx xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X361x

X373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

X = 10“

„613-112-00-5

xxxxxxxxxx (XXX);

2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Acute Tox. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1

Xxx Dam. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (prach xxxx xxxx)

xxxxxxxx: XXX = 311 xx/xx XX xxxxxx: XXX = 125 mg/kg XX

Xxxx Xxxx. 1 A; X317: C ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Xxx. 4

Xxx Xxx. 1

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: XXX = 1&xxxx;600 mg/kg XX“

„613-125-00-6

xxxxxxxxxxx (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„613-202-00-4

pymetrozin (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Aquatic Xxxxxxx 1

H351

H361fd

H410

GHS08

GHS09

Wng

H351

H361fd

H410

M = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxx

428-790-6

72963-72-5

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

XXXX XX 2

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx systém; xxxxxx, xxxxxxxxx)

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X332

X302

X371 (nervový xxxxxx; orální, xxxxxxxxx)

X410

xxxxxxxxx: XXX = 1,4 xx/x (xxxxx nebo xxxx)

xxxxxx: XXX = 550 xx/xx XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, xxxxx(xxxxxx)xxxxxxxxx

202-496-6

96-29-7

Xxxx. 1X

Xxxxx Xxx. 4

Acute Xxx. 3

XXXX XX 3

XXXX XX 1

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (horní xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (horní xxxxxxx xxxxx)

X373 (krevní oběh)

H315

H318

H317

dermální: XXX = 1&xxxx;100 xx/xx TH orální: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1X

Xxxx Irrit. 2

Xxx Xxxxx. 2

Aquatic Xxxxxxx 2

X242

X360X

X315

X319

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X242

X360X

X315

X319

X411“

3)

xxxxxxx xxxxxxxxxxxx xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 se xxxxxxx.